TGFB1 +869 T > C (rs1800470) variant is independently associated with susceptibility, laboratory activity, and TGF-β1 in patients with systemic lupus erythematosus

Autoimmunity ◽  
2021 ◽  
pp. 1-7
Author(s):  
Nicole Perugini Stadtlober ◽  
Tamires Flauzino ◽  
Lorena Flor da Rosa Franchi Santos ◽  
Tatiana Mayumi Veiga Iriyoda ◽  
Neide Tomimura Costa ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Laboratory Activity ◽  
Tgf Β1

scholarly journals TGFB1 +869 T>C (RS1800470) VARIANT IS INDEPENDENTLY ASSOCIATED WITH SUSCEPTIBILITY, LABORATORY ACTIVITY, AND TGF-Β1 IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

2021 ◽  
Author(s):  
Nicole Perugini Stadtlober ◽  
Tamires Flauzino ◽  
Lorena Flor da Rosa Franchi Santos ◽  
Tatiana Mayumi Veiga Iriyoda ◽  
Neide Tomimura Costa ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
Laboratory Activity ◽  
Tgf Β1

Levels of Transforming Growth Factor-β Are Low in Systemic Lupus Erythematosus Patients with Active Disease

2010 ◽  
Vol 37 (10) ◽  
pp. 2039-2045 ◽  
Author(s):  
ANDREA BECKER-MEROK ◽  
GRO ØSTLI EILERTSEN ◽  
JOHANNES C. NOSSENT
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Growth Factor ◽  
Disease Activity ◽  
Lupus Erythematosus ◽  
Transforming Growth Factor ◽  
Lymphocyte Subsets ◽  
Concomitant Treatment ◽  
Systemic Lupus ◽  
Cell Counts ◽  
Tgf Β1

Objective.Cytokines are central regulators of the immune response but the workings of this complex network in systemic lupus erythematosus (SLE) are not fully understood. We investigated a range of inflammatory and immune-modulating cytokines to determine their value as biomarkers for disease subsets in SLE.Methods.This was a cross-sectional study in 102 patients with SLE (87% women, disease duration 10.6 yrs). Circulating concentrations of interleukin 1β (IL-1β), IL-4, IL-6, IL-10, IL-12, IL-17, monocyte chemotactic protein 1 (MCP-1), macrophage inflammatory protein 1 (MIP-1α), MIP-1β, interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), and total transforming growth factor-β1 (TGF-β1) were related to disease activity (SLE Disease Activity Index; SLEDAI), lymphocyte subsets, autoantibody levels, accrued damage (Systemic Lupus International Collaborating Clinics/ACR Damage Index; SDI), and concomitant treatment.Results.Patients with SLE had lower levels of TGF-β1 (p = 0.01) and IL-1β (p = 0.0004) compared to controls. TGF-β1 levels were lower in patients with SLEDAI scores 1–10 and SDI > 3; and were correlated with CD4+, CD8+, and natural killer cell counts; and were independent of steroid or cytotoxic drug use. Treatment with cardiovascular drugs was associated with lower IL-12 levels. No consistent disease associations existed for the other cytokines investigated.Conclusion.Lower TGF-β1 was the most consistent cytokine abnormality in patients with SLE. The associations with disease activity, lymphocyte subsets, and damage suggest that TGF-β1 may be a therapeutic target of interest in SLE.

scholarly journals HAPLOTYPES OF FOXP3 GENETIC VARIANTS ARE ASSOCIATED WITH SUSCEPTIBILITY, AUTOANTIBODIES, AND TGF-Β1 IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS.

2021 ◽  
Author(s):  
Nicole Perugini Stadtlober ◽  
Tamires Flauzino ◽  
Lorena Flor da Rosa Franchi Santos ◽  
Tatiana Mayumi Veiga Iriyoda ◽  
Neide Tomimura Costa ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Genetic Variants ◽  
Systemic Lupus ◽  
Tgf Β1

scholarly journals Comparison of Plasma Cytokine Levels before and after Treatment with Rituximab in Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus-Associated Polyautoimmunity

2018 ◽  
Vol 59 (3) ◽  
pp. 1-16 ◽  
Author(s):  
Julián Esteban Barahona Correa ◽  
Manuel Antonio Franco Cortés ◽  
Juana Ángel Uribe ◽  
Luz Stella Rodríguez Camacho
Keyword(s):  
Rheumatoid Arthritis ◽  
Systemic Lupus Erythematosus ◽  
B Cells ◽  
Lupus Erythematosus ◽  
Clinical Status ◽  
Future Research ◽  
Systemic Lupus ◽  
Tnf Α ◽  
Cytokine Levels ◽  
Tgf Β1

Introduction: Coexistence of more than one autoimmune disease (AD) in a single patient is known as polyautoimmunity, and may be seen in up to 35% of patients with ADs. The elimination of B-cells using Rituximab (RTX) improves clinical status in different ADs. The role of cytokine production by B-cells is unclear in systemic lupus erythematosus (SLE) and polyautoimmunity. Methods: As an exploratory study, plasma from 11 patients with either rheumatoid arthritis (RA) or SLE-associated polyautoimmunity was assessed prior and 6 months after therapy with RTX. Eight healthy individuals were used as controls. Cytokine levels were measured using ELISA (IFN-α and TGF-β1) or Cytometric Bead Array (TNF-α, IL-1β, IL-6, IL-8, IL-10, and IL-12p70). Results: Prior to RTX, IL-6 was only elevated in RA and IL-8 was elevated in both RA and SLE-associated polyautoimmunity, compared with controls. After RTX, significant decreases of IL-6 in RA and IL-8 in SLE-associated polyautoimmunity were observed. Levels of other cytokines measured were either similar (IFN-α, TGF β1) or below the detection limit (TNF-α, IL-1β, IL-10, IL-12p70) for both patients and controls. Conclusion:Our data highlight the importance of B-cell cytokine secretion in RA and SLE-associated polyautoimmunity, and suggest a differential role in each pathology. A significant increase of IL-8 prior to RTX in both groups, and a significant decrease after therapy only in SLE-associated polyautoimmunity support the potential of IL-8 as a therapeutic target. The heterogeneity of the polyautoimmunity patient population highlights the importance of the selection of specific subsets in future research.

Sign in / Sign up

Export Citation Format

Share Document